Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01272167
Other study ID # CHU-0085
Secondary ID 2009-A00960-57
Status Completed
Phase N/A
First received January 3, 2011
Last updated July 4, 2014
Start date March 2010
Est. completion date December 2011

Study information

Verified date July 2014
Source University Hospital, Clermont-Ferrand
Contact n/a
Is FDA regulated No
Health authority France: Ministry of Health
Study type Interventional

Clinical Trial Summary

Epidemiological studies definitively show that fruit and vegetable consumption is an important factor for the prevention of age-related diseases such as cardiovascular diseases (CVD) and osteoporosis. Citrus fruits are among the fruits which are the most frequently consumed worldwide, essentially as juices.

Citrus fruits are the exclusive sources of a particular class of dietary flavonoids, namely flavanones. Grapefruit consumed as whole fruit or juice corresponds to a quantitatively significant source of a specific flavanone called naringin.


Description:

Epidemiological studies definitively show that fruit and vegetable consumption is an important factor for the prevention of age-related diseases such as cardiovascular diseases (CVD) and osteoporosis. Citrus fruits are among the fruits which are the most frequently consumed worldwide, essentially as juices.

Citrus fruits are the exclusive sources of a particular class of dietary flavonoids, namely flavanones. Grapefruit consumed as whole fruit or juice corresponds to a quantitatively significant source of a specific flavanone called naringin.

Some scientific data obtained from animal studies or in vitro experiments suggested that flavanones could exert positive effects on several biomarkers of the cardiovascular or osteoporosis risks. However, until now, the clinical proof of the efficacy of these compounds is far to be obtained and more clinical trials are needed.

The main goals of this project are (1) to characterize the effect of a long-term grapefruit juice consumption on both vascular and bone protections and (2) to assess the specific role of naringin, in these potential protective effects.

To reach these goals, a randomized, cross-over clinical trial will be performed on 52 healthy post-menopausal women (50 to 65 years old, 3 to 10 years since menopause, waist > 88 cm). Such a population shares an increased risk of CVD and osteoporosis.

They will consume for two periods of 6 months either 340 ml of grapefruit juice or a control isoenergetic beverage.

Major outcomes will be measured at baseline and at the end of each experimental period.


Recruitment information / eligibility

Status Completed
Enrollment 52
Est. completion date December 2011
Est. primary completion date December 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 50 Years to 65 Years
Eligibility Inclusion Criteria:

- Caucasian healthy post-menopausal women

- 19= BMI =29 and waist measurement > 88 cm

Exclusion Criteria:

- Metabolic diseases

- Hypertension

- Taking CYP3A4-metabolized drugs

- Taking blood lipids lowering drugs or antihypertensive drugs

- Hypercholesterolemia with HDL < 1.30 mmol/L (i.e. < 0.5 g/L)

- Osteoporosis (defined by T-score of -2.5 SD at hip and/or lumbar spine)

- Taking hormone replacement therapy (HRT)

- Smokers

- Taking dietary supplements

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Behavioral:
Long-term grapefruit juice consumption
The main goals of this project are (1) to characterize the effect of a long-term grapefruit juice consumption on both vascular and bone protections and (2) to assess the specific role of naringin, in these potential protective effects.

Locations

Country Name City State
France CHU Clermont-Ferrand Clermont-Ferrand

Sponsors (6)

Lead Sponsor Collaborator
University Hospital, Clermont-Ferrand 63122 Saint-Genès Champanelle, Equipe MiMes, FRANCE, INRA de Clermont-Fd / Theix, UMR 1019 Unité de Nutrition Humaine

Country where clinical trial is conducted

France,